vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $12.5M, roughly 1.6× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -541.1%, a 542.4% gap on every dollar of revenue. On growth, AGIOS PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (86.1% vs -0.7%). Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 12.5%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
AGIO vs SLSN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $12.5M |
| Net Profit | $-108.0M | $163.0K |
| Gross Margin | 90.6% | 27.5% |
| Operating Margin | -608.9% | 1.5% |
| Net Margin | -541.1% | 1.3% |
| Revenue YoY | 86.1% | -0.7% |
| Net Profit YoY | -11.9% | 129.2% |
| EPS (diluted) | $-1.86 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.0M | $12.5M | ||
| Q3 25 | $12.9M | $14.6M | ||
| Q2 25 | $12.5M | $20.4M | ||
| Q1 25 | $8.7M | $14.6M | ||
| Q4 24 | $10.7M | $12.6M | ||
| Q3 24 | $9.0M | $16.9M | ||
| Q2 24 | $8.6M | $13.0M | ||
| Q1 24 | $8.2M | $9.9M |
| Q4 25 | $-108.0M | $163.0K | ||
| Q3 25 | $-103.4M | $-1.1M | ||
| Q2 25 | $-112.0M | $2.7M | ||
| Q1 25 | $-89.3M | $80.0K | ||
| Q4 24 | $-96.5M | $-559.0K | ||
| Q3 24 | $947.9M | $3.0M | ||
| Q2 24 | $-96.1M | $856.0K | ||
| Q1 24 | $-81.5M | $893.0K |
| Q4 25 | 90.6% | 27.5% | ||
| Q3 25 | 87.0% | 23.1% | ||
| Q2 25 | 86.3% | 28.9% | ||
| Q1 25 | 87.6% | 23.1% | ||
| Q4 24 | 88.3% | 22.0% | ||
| Q3 24 | 91.3% | 36.2% | ||
| Q2 24 | 82.6% | 28.7% | ||
| Q1 24 | 92.3% | 36.3% |
| Q4 25 | -608.9% | 1.5% | ||
| Q3 25 | -907.4% | -5.4% | ||
| Q2 25 | -1020.1% | 9.4% | ||
| Q1 25 | -1222.0% | 1.8% | ||
| Q4 24 | -1165.3% | -1.8% | ||
| Q3 24 | -1146.9% | 19.0% | ||
| Q2 24 | -1228.3% | 8.0% | ||
| Q1 24 | -1124.3% | 11.3% |
| Q4 25 | -541.1% | 1.3% | ||
| Q3 25 | -803.1% | -7.7% | ||
| Q2 25 | -899.4% | 13.1% | ||
| Q1 25 | -1023.3% | 0.5% | ||
| Q4 24 | -899.6% | -4.4% | ||
| Q3 24 | 10574.7% | 18.1% | ||
| Q2 24 | -1115.7% | 6.6% | ||
| Q1 24 | -995.8% | 9.0% |
| Q4 25 | $-1.86 | $0.00 | ||
| Q3 25 | $-1.78 | $-0.02 | ||
| Q2 25 | $-1.93 | $0.04 | ||
| Q1 25 | $-1.55 | $0.00 | ||
| Q4 24 | $-1.44 | $0.00 | ||
| Q3 24 | $16.22 | $0.04 | ||
| Q2 24 | $-1.69 | $0.01 | ||
| Q1 24 | $-1.45 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $17.6M |
| Total Assets | $1.3B | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.1M | $1.3M | ||
| Q3 25 | $92.7M | $429.0K | ||
| Q2 25 | $80.9M | $4.1M | ||
| Q1 25 | $79.0M | $1.8M | ||
| Q4 24 | $76.2M | $1.4M | ||
| Q3 24 | $253.7M | $2.9M | ||
| Q2 24 | $84.5M | $2.4M | ||
| Q1 24 | $118.8M | $2.0M |
| Q4 25 | $1.2B | $17.6M | ||
| Q3 25 | $1.3B | $17.2M | ||
| Q2 25 | $1.4B | $18.2M | ||
| Q1 25 | $1.5B | $15.2M | ||
| Q4 24 | $1.5B | $14.9M | ||
| Q3 24 | $1.6B | $15.2M | ||
| Q2 24 | $660.5M | $11.9M | ||
| Q1 24 | $743.9M | $5.0M |
| Q4 25 | $1.3B | $50.1M | ||
| Q3 25 | $1.4B | $54.0M | ||
| Q2 25 | $1.5B | $60.0M | ||
| Q1 25 | $1.6B | $57.0M | ||
| Q4 24 | $1.7B | $50.0M | ||
| Q3 24 | $1.8B | $48.0M | ||
| Q2 24 | $773.1M | $40.8M | ||
| Q1 24 | $849.7M | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | $1.8M |
| Free Cash FlowOCF − Capex | $-97.3M | — |
| FCF MarginFCF / Revenue | -487.5% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-96.2M | $1.8M | ||
| Q3 25 | $-88.2M | $-2.5M | ||
| Q2 25 | $-77.1M | $-654.0K | ||
| Q1 25 | $-111.5M | $-7.2M | ||
| Q4 24 | $-133.2M | $2.2M | ||
| Q3 24 | $-84.2M | $4.2M | ||
| Q2 24 | $-72.6M | $-565.0K | ||
| Q1 24 | $-99.9M | $-3.9M |
| Q4 25 | $-97.3M | — | ||
| Q3 25 | $-89.7M | — | ||
| Q2 25 | $-78.0M | — | ||
| Q1 25 | $-112.3M | — | ||
| Q4 24 | $-134.1M | $-404.0K | ||
| Q3 24 | $-84.6M | $2.8M | ||
| Q2 24 | $-72.7M | $-1.0M | ||
| Q1 24 | $-100.0M | $-3.9M |
| Q4 25 | -487.5% | — | ||
| Q3 25 | -696.5% | — | ||
| Q2 25 | -626.2% | — | ||
| Q1 25 | -1286.4% | — | ||
| Q4 24 | -1250.1% | -3.2% | ||
| Q3 24 | -944.2% | 16.6% | ||
| Q2 24 | -844.4% | -8.0% | ||
| Q1 24 | -1221.2% | -39.9% |
| Q4 25 | 5.6% | — | ||
| Q3 25 | 12.1% | — | ||
| Q2 25 | 7.0% | — | ||
| Q1 25 | 8.8% | — | ||
| Q4 24 | 9.0% | 20.6% | ||
| Q3 24 | 4.7% | 8.3% | ||
| Q2 24 | 1.8% | 3.7% | ||
| Q1 24 | 1.7% | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.09× | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
